APA (7th ed.) Citation

K, D., MH, F., R, R., JS, H., JO, C., M, A., . . . B, A. (2025). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Long-Acting FGF21 Analog Zalfermin. Clinical and translational science, 18(12), e70435. https://doi.org/10.1111/cts.70435

Chicago Style (17th ed.) Citation

K, Dahl, et al. "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Long-Acting FGF21 Analog Zalfermin." Clinical and Translational Science 18, no. 12 (2025): e70435. https://doi.org/10.1111/cts.70435.

MLA (9th ed.) Citation

K, Dahl, et al. "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Long-Acting FGF21 Analog Zalfermin." Clinical and Translational Science, vol. 18, no. 12, 2025, p. e70435, https://doi.org/10.1111/cts.70435.